CYP17 gene polymorphism in relation to breast cancer risk: a case-control study

Breast Cancer Research

Table 3 Breast cancer risk in relation to CYP17 genotype, stratified by histopathological type, menopausal hormones or diabetes mellitus

	CYP17 genotype						P for interaction
	A1/A1		A1/A2		A2/A2
	Cases/controls^a	OR^b(CI)	Cases/controls^a	OR^b(CI)	Cases/controls^a	OR^b(CI)
All cancers	550/488	1 (reference)	711/638	1.0 (0.9–1.2)	238/212	1.0 (0.8–1.3)
Ductal cancers	420/488	1 (reference)	510/638	1.0 (0.8–1.1)	180/212	1.0 (0.8–1.3)
Lobular cancers	56/488	1 (reference)	90/638	1.3 (0.9–1.8)	24/212	1.1 (0.6–1.8)
Duration of menopausal hormone use(all cancers)
Never	390/370	1 (reference)	469/473	0.9 (0.8–1.1)	165/154	1.0 (0.8–1.3)
Any kind
<4	59/50	1 (reference)	96/74	1.2 (0.7–2.0)	26/25	1.0 (0.5–2.1)
≥4	101/68	1 (reference)	146/91	1.2 (0.8–1.9)	47/33	1.0 (0.6–1.7)	0.668
Estrogen only
<4	28/22	1 (reference)	43/33	1.1 (0.5–2.3)	7/11	0.6 (0.2–1.8)
≥4	39/23	1 (reference)	42/30	1.0 (0.5–2.1)	15/13	0.7 (0.3–1.9)	0.703
Estrogen + progestin
<4	42/41	1 (reference)	75/66	1.2 (0.7–2.1)	23/21	1.2 (0.6–2.5)
≥4	64/47	1 (reference)	108/62	1.3 (0.8–2.2)	34/20	1.2 (0.6–2.4)	0.723
Self-reported diabetes mellitus (all cancers)
No	502/448	1 (reference)	644/592	1.0 (0.8–1.2)	217/194	1.0 (0.8–1.3)
Yes	48/40	1 (reference)	67/46	1.3 (0.7–2.2)	21/18	1.1 (0.5–2.3)	0.259

^aIncluding only cases and controls with complete information on menopausal hormones and diabetes mellitus. ^bAnalyses were conditioned on age (5-year age groups), menopausal estrogen only use (never, <4 years or ≥4 years), use of estrogen in combination with progestin (never, <4 years or ≥4 years) and diabetes mellitus (yes or no). CI, confidence interval; OR, odds ratio.

ISSN: 1465-542X